Harbour Investments Inc. Purchases 160 Shares of AstraZeneca PLC (NASDAQ:AZN)

Harbour Investments Inc. lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,805 shares of the company’s stock after acquiring an additional 160 shares during the period. Harbour Investments Inc.’s holdings in AstraZeneca were worth $686,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. McClarren Financial Advisors Inc. boosted its stake in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares in the last quarter. GHP Investment Advisors Inc. bought a new position in shares of AstraZeneca in the second quarter worth about $26,000. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca in the 3rd quarter valued at approximately $28,000. Pathway Financial Advisers LLC bought a new stake in shares of AstraZeneca during the 1st quarter valued at approximately $29,000. Finally, CANADA LIFE ASSURANCE Co increased its position in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AZN. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $63.23 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 0.93. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The firm has a market cap of $196.05 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The firm’s fifty day moving average is $75.03 and its 200-day moving average is $78.20.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the business earned $0.87 EPS. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. Sell-side analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.